Insmed to Present New Data Across Its Respiratory Portfolio at CHEST 2026 and IDWeek 2026
Insmed announced that new data across its respiratory portfolio will be presented at CHEST 2026 (Oct 18-21, Phoenix) and IDWeek 2026 (Oct 21-24, Washington, D.C.). At CHEST, three late-breaking TPIP abstracts cover long-term data in PAH and PH-ILD, plus a post hoc analysis of the Phase 3 ASPEN study of BRINSUPRI in bronchiectasis. At IDWeek, two ARIKAYCE abstracts include Phase 3b ENCORE results on amikacin and macrolide resistance in newly diagnosed MAC lung disease.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.